These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 32470789)

  • 1. Survival of COVID-19 patients requires precise immune regulation: The hypothetical immunoprotective role of nicotinic agonists.
    Allahverdi Khani M; SalehiRad M; Darbeheshti S; Motaghinejad M
    Med Hypotheses; 2020 Oct; 143():109871. PubMed ID: 32470789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How nicotine can inhibit cytokine storm in the lungs and prevent or lessen the severity of COVID-19 infection?
    Kloc M; Ghobrial RM; Kubiak JZ
    Immunol Lett; 2020 Aug; 224():28-29. PubMed ID: 32522666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Multiple Effects of SGLT2 Inhibitors Suggest Potential Benefit in COVID-19 Patients.
    Soni S; Dyck JRB
    Can J Cardiol; 2020 Oct; 36(10):1691.e3. PubMed ID: 32717278
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical outcomes of coronavirus disease 2019 (COVID-19) in cancer patients with prior exposure to immune checkpoint inhibitors.
    Wu Q; Chu Q; Zhang H; Yang B; He X; Zhong Y; Yuan X; Chua MLK; Xie C
    Cancer Commun (Lond); 2020 Aug; 40(8):374-379. PubMed ID: 32666636
    [No Abstract]   [Full Text] [Related]  

  • 5. Cytokine Storm Drugs Move from CAR T to COVID-19.
    Cancer Discov; 2020 Jul; 10(7):OF8. PubMed ID: 32371479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can Colchicine as an Old Anti-Inflammatory Agent Be Effective in COVID-19?
    Nasiripour S; Zamani F; Farasatinasab M
    J Clin Pharmacol; 2020 Jul; 60(7):828-829. PubMed ID: 32445400
    [No Abstract]   [Full Text] [Related]  

  • 7. SARS-CoV-2-A Tough Opponent for the Immune System.
    Nasab MG; Saghazadeh A; Rezaei N
    Arch Med Res; 2020 Aug; 51(6):589-592. PubMed ID: 32532524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Should we unstress SARS-CoV-2 infected cells?
    Csukasi F; Rico G; Becerra J; Duran I
    Cytokine Growth Factor Rev; 2020 Aug; 54():3-5. PubMed ID: 32563554
    [No Abstract]   [Full Text] [Related]  

  • 9. COVID-19 and Hypercoagulability.
    Sholzberg M
    Clin Adv Hematol Oncol; 2020 Jul; 18(7):386-389. PubMed ID: 32903249
    [No Abstract]   [Full Text] [Related]  

  • 10. Nicotinic Cholinergic System and COVID-19: In Silico Identification of an Interaction between SARS-CoV-2 and Nicotinic Receptors with Potential Therapeutic Targeting Implications.
    Farsalinos K; Eliopoulos E; Leonidas DD; Papadopoulos GE; Tzartos S; Poulas K
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32823591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2 infection: The role of cytokines in COVID-19 disease.
    Costela-Ruiz VJ; Illescas-Montes R; Puerta-Puerta JM; Ruiz C; Melguizo-Rodríguez L
    Cytokine Growth Factor Rev; 2020 Aug; 54():62-75. PubMed ID: 32513566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surviving COVID-19: A disease tolerance perspective.
    Ayres JS
    Sci Adv; 2020 May; 6(18):eabc1518. PubMed ID: 32494691
    [No Abstract]   [Full Text] [Related]  

  • 13. Pros and cons of corticosteroid therapy for COVID-19 patients.
    Mattos-Silva P; Felix NS; Silva PL; Robba C; Battaglini D; Pelosi P; Rocco PRM; Cruz FF
    Respir Physiol Neurobiol; 2020 Sep; 280():103492. PubMed ID: 32659271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute inflammation and pathogenesis of SARS-CoV-2 infection: Cannabidiol as a potential anti-inflammatory treatment?
    Costiniuk CT; Jenabian MA
    Cytokine Growth Factor Rev; 2020 Jun; 53():63-65. PubMed ID: 32467020
    [No Abstract]   [Full Text] [Related]  

  • 15. Successful use of methylprednisolone for treating severe COVID-19.
    Liu J; Zheng X; Huang Y; Shan H; Huang J
    J Allergy Clin Immunol; 2020 Aug; 146(2):325-327. PubMed ID: 32479759
    [No Abstract]   [Full Text] [Related]  

  • 16. Potential protective and therapeutic role of immune checkpoint inhibitors against viral infections and COVID-19.
    Gatto L; Franceschi E; Nunno VD; Brandes AA
    Immunotherapy; 2020 Oct; 12(15):1111-1114. PubMed ID: 32594820
    [No Abstract]   [Full Text] [Related]  

  • 17. How does COVID-19 kill? Uncertainty is hampering doctors' ability to choose treatments.
    Ledford H
    Nature; 2020 Apr; 580(7803):311-312. PubMed ID: 32273618
    [No Abstract]   [Full Text] [Related]  

  • 18. Protective Effect of Epigallocatechin-3-Gallate (EGCG) in Diseases with Uncontrolled Immune Activation: Could Such a Scenario Be Helpful to Counteract COVID-19?
    Menegazzi M; Campagnari R; Bertoldi M; Crupi R; Di Paola R; Cuzzocrea S
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytokine Storm: Is it the only major death factor in COVID-19 patients? Coagulation role.
    Magro G
    Med Hypotheses; 2020 Sep; 142():109829. PubMed ID: 32428809
    [No Abstract]   [Full Text] [Related]  

  • 20. [Not Available].
    Balavoine JF
    Rev Med Suisse; 2020 May; 16(695):1126. PubMed ID: 32462848
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.